MAPT and Alzheimer disease: Moreover, O-linked β-N-acetylglucosamine (O-GlcNAc) modification of tau has been found in AD patients, suggesting that proteostatic signaling is designed to counteract tau phosphorylation and aggregation to slow disease progression (Wang et al., 2017; Wang et al., 2020).